Programmed death-ligand 2 (PD-L2) expressed on the surface of cancer cells could induce immunosuppression through interaction with PD-1 in immune cells [5, 6], and blocking this interaction gave rise to an impressive clinical benefit in various of cancers [7–14]. The gene discussed is PDCD1LG2; the disease is cancer.